A pharmaceutical composition comprising a cell transfected with a gene encoding a light-sensitive channel for use in the treatment of a disease or disorder associated with suppressed, slow, irregular or unsynchronized cardiac activity in a human patient upon exposure of the composition to light after the composition is introduced by direct injection into a plurality of sites of contractile tissue in the heart of the patient.
